Cyclica Announces the Close of its Series A2 Financing Round
Toronto, ON, Canada (July 26, 2017) – Cyclica is pleased to announce that it has completed a $2.25M Series A2 financing, an extension of the $2.4M Series A1 financing round that closed in September 2016. The syndicated investment group was led by GreenSky Accelerator Fund II, with co-investment by Epic Capital, Uni-Innovate Group, HH&E Ventures, and new […]
Cyclica Announces the Addition of Dr. Andy Hope to its Management Team
TORONTO, ON, CANADA (July 24, 2017)- Cyclica Inc. is pleased to announce that it has added Dr. Andy Hope as VP of Sales and Business Development. Andy brings to Cyclica a rich background and over 25 years experience in sales and business development in the life sciences industry providing complex solutions and services to pharmaceutical and […]
Cyclica Announces the Appointment of John F. Conway to its Scientific Advisory Board
TORONTO, ON, CANADA (June 16, 2017)- Cyclica Inc. is pleased to announce the appointment of John F. Conway to its Scientific Advisory Board (SAB). John brings to Cyclica his deep expertise in computational drug discovery and cheminformatics, as well as his extensive 25+ years of experience within the pharmaceutical industry. Currently, John serves as Global Director […]
Cyclica Announces Collaboration with Drs. Angus McQuibban and Peter Lewis of the University of Toronto to Elucidate Mechanism of Action of Lead Drug Candidates for Parkinson’s Disease
TORONTO, ON, CANADA– (April 5, 2017) — The labs of Dr. Angus McQuibban and Dr. Peter Lewis at the University of Toronto and Cyclica Inc., all located in Toronto, Canada, have initiated a collaboration with Cyclica to use its Ligand Express™ drug discovery informatics platform. Both research groups will use Cyclica’s structure-based, proteome-wide screening technology, Ligand Express™, to determine the […]
Cyclica Announces Collaboration with Dr. Cecilia Sanchez of Tulane University to Identify Novel Drug Targets for Systemic Scleroderma
TORONTO, ON, CANADA and NEW ORLEANS, LA, USA (February 16, 2017) – The Sanchez labat Tulane University, located in New Orleans, LA, USA, and Cyclica Inc., located in Toronto, ON, have engaged in a collaboration using Cyclica’s Ligand Express™ drug discovery informatics platform. Dr. Cecilia Sanchez will use Cyclica’s structure-based, proteome-wide screening technology, Ligand Express™, to identify novel drug […]
Cyclica and Quinten Form Alliance to Create a First-in-Class Cloud-Based Drug Discovery Informatics Ecosystem
TORONTO, ON, CANADA and PARIS, FRANCE (February 13, 2017) – Quinten, located in Paris, France, and CyclicaInc., located in Toronto, Canada, have jointly formed an alliance to create a Drug Discovery Informatics Ecosystem. The goal of the alliance is to offer pharmaceutical companies, who are seeking productivity gains in discovering and developing lead molecules, a seamless end-to-end cloud-based […]
Cyclica and CDRD Commence Revolutionary Drug Discovery Pilot Study to Identify Novel Drug Targets for a Neurodegenerative Disease
Toronto, ON and Vancouver, BC (February 9, 2017) – The Centre for Drug Research and Development (CDRD), located in Vancouver BC, andCyclica Inc., a Canadian company located in Toronto, ON, have engaged in a pilot study using Cyclica’s Ligand Express™ drug discovery informatics platform. CDRD’s Screening team led by Dr. Tom Pfeifer, will use Cyclica’s structure-based, […]
2017 — Looking ahead for the New Year
2016 was a remarkable and highly productive year for us at Cyclica. From scientific and technological development and validation, brand awareness, commercial traction, and financing, we immersed ourselves in numerous core endeavours, and hustled to reach our goals and objectives. At the core of Cyclica is its people; they are our most valuable asset. I […]